(CLDX) Celldex Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.400m USD | Total Return: 55.4% in 12m

Monoclonal Antibodies, Bispecific Antibodies, Therapeutic Proteins
Total Rating 32
Safety 32
Buy Signal -0.48
Biotechnology
Industry Rotation: -7.0
Market Cap: 2.40B
Avg Turnover: 23.7M
Risk 3d forecast
Volatility51.6%
VaR 5th Pctl8.48%
VaR vs Median-0.21%
Reward TTM
Sharpe Ratio0.92
Rel. Str. IBD73.1
Rel. Str. Peer Group43.3
Character TTM
Beta1.089
Beta Downside1.036
Hurst Exponent0.470
Drawdowns 3y
Max DD70.84%
CAGR/Max DD0.00
CAGR/Mean DD0.00
EPS (Earnings per Share) EPS (Earnings per Share) of CLDX over the last years for every Quarter: "2021-03": -0.42, "2021-06": -0.34, "2021-09": -0.45, "2021-12": -0.43, "2022-03": -0.49, "2022-06": -0.59, "2022-09": -0.57, "2022-12": -0.56, "2023-03": -0.62, "2023-06": -0.65, "2023-09": -0.81, "2023-12": -0.83, "2024-03": -0.56, "2024-06": -0.54, "2024-09": -0.64, "2024-12": -0.71, "2025-03": -0.81, "2025-06": -0.85, "2025-09": -1.01, "2025-12": -1.22, "2026-03": -1.18,
Last SUE: -0.42
Qual. Beats: 0
Revenue Revenue of CLDX over the last years for every Quarter: 2021-03: 0.685, 2021-06: 3.48, 2021-09: 0.153, 2021-12: 0.334, 2022-03: 0.174, 2022-06: 0.163, 2022-09: 0.407, 2022-12: 1.613, 2023-03: 0.967, 2023-06: 0.268, 2023-09: 1.517, 2023-12: 4.131, 2024-03: 0.156, 2024-06: 2.498, 2024-09: 3.191, 2024-12: 1.175, 2025-03: 0.695, 2025-06: 0.73, 2025-09: 0, 2025-12: 0.075, 2026-03: 0.015,
Rev. CAGR: -36.49%
Rev. Trend: -54.0%
Last SUE: -0.64
Qual. Beats: 0

Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

Choppy Below Avwap Earnings

Tailwinds

Confidence

Description: CLDX Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical firm focused on developing monoclonal and bispecific antibodies to treat severe inflammatory, allergic, and autoimmune conditions. The company’s primary clinical asset, Barzolvolimab, targets the KIT receptor to inhibit mast cell activity in diseases such as chronic urticaria and atopic dermatitis. Its pipeline also includes CDX-622, a bispecific candidate designed to neutralize inflammatory pathways and deplete mast cells.

The biotechnology sector typically follows a high-risk, research-intensive business model where value is driven by clinical trial milestones and regulatory approvals. Unlike traditional pharmaceutical companies that rely on established sales, clinical-stage firms often prioritize intellectual property development and strategic partnerships to fund long-term R&D cycles.

Investors may find it useful to review ValueRay for further data on these clinical developments. Celldex operates out of its headquarters in Hampton, New Jersey, maintaining a focus on mast cell mediated diseases where current treatment options remain insufficient for patient needs.

Headlines to Watch Out For
  • Barzolvolimab clinical trial results for chronic urticaria dictate long-term valuation
  • Expansion into eosinophilic esophagitis and atopic dermatitis markets increases total addressable market
  • High research and development expenditures necessitate future dilutive capital raises
  • Regulatory approval timelines for KIT receptor inhibitors impact commercialization prospects
  • Competition from established biologics in the mast cell disease space pressures market share
Piotroski VR-10 (Strict) 0.0
Net Income: -283.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.44 > 0.02 and ΔFCF/TA -20.91 > 1.0
NWC/Revenue: 49.7k% < 20% (prev 8.75k%; Δ 41.0k% < -1%)
CFO/TA -0.43 > 3% & CFO -222.2m > Net Income -283.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.92 > 1.5 & < 3
Outstanding Shares: last quarter (66.6m) vs 12m ago 0.28% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.13% > 50% (prev 1.02%; Δ -0.89% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.80 (Total Current Assets 459.2m - Total Current Liabilities 51.5m) / Total Assets 511.3m
B: -3.70 (Retained Earnings -1.89b / Total Assets 511.3m)
C: -0.48 (EBIT TTM -303.3m / Avg Total Assets 625.4m)
D: -34.35 (Book Value of Equity -1.89b / Total Liabilities 55.0m)
Altman-Z'' = -46.16 = D
Beneish M -2.88
DSRI: 1.99 (Receivables 230k/1.06m, Revenue 820k/7.56m)
GMI: 0.68 (GM 100.0% / 68.22%)
AQI: 1.64 (AQ_t 0.08 / AQ_t-1 0.05)
SGI: 0.11 (Revenue 820k / 7.56m)
TATA: -0.12 (NI -283.7m - CFO -222.2m) / TA 511.3m)
Beneish M = -2.88 (Cap -4..+1) = A
What is the price of CLDX shares?

As of May 26, 2026, the stock is trading at USD 30.73 with a total of 582,900 shares traded.
Over the past week, the price has changed by -1.95%, over one month by -8.70%, over three months by -0.29% and over the past year by +55.36%.

Is CLDX a buy, sell or hold?

Celldex Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy CLDX.

  • StrongBuy: 12
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CLDX price?
Analysts Target Price 58.4 90.1%
Celldex Therapeutics (CLDX) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 2.40b (2.40b USD * 1.0 USD.USD)
P/S = 2774.899
P/B = 5.3162
Revenue TTM = 820k USD
EBIT TTM = -303.3m USD
EBITDA TTM = -299.9m USD
Long Term Debt = 443k USD (estimated: total debt 1.91m - short term 1.47m)
Short Term Debt = 1.47m USD (from shortTermDebt, last quarter)
Debt = 1.91m USD (from shortLongTermDebtTotal, last quarter) (leases 1.91m already included)
Net Debt = -449.6m USD (calculated: Debt 1.91m - CCE 451.5m)
Enterprise Value = 1.95b USD (2.40b + Debt 1.91m - CCE 451.5m)
 Interest Coverage Ratio = unknown (Ebit TTM -303.3m / Interest Expense TTM 0.0)
 EV/FCF = -8.63x (Enterprise Value 1.95b / FCF TTM -226.0m)
FCF Yield = -11.58% (FCF TTM -226.0m / Enterprise Value 1.95b)
 FCF Margin = -27.6k% (FCF TTM -226.0m / Revenue TTM 820k)
 Net Margin = -34.6k% (Net Income TTM -283.7m / Revenue TTM 820k)
 Gross Margin = unknown ((Revenue TTM 820k - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 3.82 (Enterprise Value 1.95b / Total Assets 511.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -239.6m (EBIT -303.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.92 (Total Current Assets 459.2m / Total Current Liabilities 51.5m)
Debt / Equity = 0.00 (Debt 1.91m / totalStockholderEquity, last quarter 456.2m)
 Debt / EBITDA = 1.50 (negative EBITDA) (Net Debt -449.6m / EBITDA -299.9m)
 Debt / FCF = 1.99 (negative FCF - burning cash) (Net Debt -449.6m / FCF TTM -226.0m)
 Total Stockholder Equity = 559.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.36% (Net Income -283.7m / Total Assets 511.3m)
RoE = -11.57% (Net Income TTM -283.7m / Total Stockholder Equity 2.45b)
RoCE = -12.37% (EBIT -303.3m / Capital Employed (Equity 2.45b + L.T.Debt 443k))
 RoIC = -53.65% (negative operating profit) (NOPAT -239.6m / Invested Capital 446.5m)
 WACC = 9.80% (E(2.40b)/V(2.40b) * Re(9.81%) + D(1.91m)/V(2.40b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 11.57%
 [DCF] Fair Price = unknown (Cash Flow -226.0m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: -54.03 | Revenue CAGR: -36.49% | SUE: -0.64 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.06 | Chg30d=+11.42% | Revisions=+50% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-1.08 | Chg30d=+12.34% | Revisions=+33% | Analysts=9
EPS current Year (2026-12-31): EPS=-4.39 | Chg30d=+7.14% | Revisions=+60% | GrowthEPS=-12.6% | GrowthRev=+70.5%
EPS next Year (2027-12-31): EPS=-4.55 | Chg30d=+4.47% | Revisions=+45% | GrowthEPS=-3.6% | GrowthRev=+241.9%
[Analyst] Revisions Ratio: +60%